According to a BioSpace report, a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval for the use of oral treprostinil diethanolamine sustained release tablets for the treatment of pulmonary arterial hypertension (PAH)

[Note: Treprostinil is not licensed in the UK.]